Management to host conference call today at 4:30 p.m. ET

STAMFORD, Conn. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the

STAMFORD, Conn. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced

Study to inform dose selection and design of Phase 2 trial in non-hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP)

Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation

STAMFORD, Conn. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced

Phase 3 pivotal program in hemodialysis patients expected to commence in Q4 2017

STAMFORD, Conn. , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced

Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek STAMFORD, Conn. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed

Conference call today at 4:30 p.m. ET